Celgene Prices $1.5 Billion of Senior Unsecured Notes

Celgene Corporation

today announced the successful pricing of two series of senior unsecured notes for an aggregate principal amount of $1.5 billion. Of these notes, $500 million will mature in 2017 and will bear interest at an annual rate of 1.900%, and $1 billion will mature in 2022 and will bear interest at an annual rate of 3.250%. The 1.900% notes due 2017, and the 3.250% notes due 2022 were priced to yield 1.945% and 3.256%, respectively. Celgene expects to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of Celgene's clinical and pre-clinical programs, capital expenditures, general corporate development activities and meeting working capital needs. The offering is expected to close on August 9, 2012.